Literature DB >> 2841358

Pre-beta-very low density lipoproteins as precursors of beta-very low density lipoproteins. A model for the pathogenesis of familial dysbetalipoproteinemia (type III hyperlipoproteinemia).

D A Chappell1.   

Abstract

The physical, chemical, and receptor binding properties of very low density lipoprotein (VLDL) fractions from familial dysbetalipoproteinemic (dys-beta) subjects, homozygous for apolipoprotein (apo-) E2 (E2/2 phenotype), and subjects with the E3/3 phenotype were studied to gain insights into the pathogenesis of dysbetalipoproteinemia, a disorder characterized by the presence of beta-VLDL in the plasma. Pre-beta-VLDL from dys-beta subjects were larger (27 vs. 17 x 10(6) D) and more triglyceride rich (68 vs. 43% dry weight) than beta-VLDL. Pre-beta-VLDL predominated in the Sf greater than 100 flotation fraction, whereas beta-VLDL predominated in the Sf 20-60 fraction. Because lipolysis converts large VLDL (Sf greater than 100) in vivo to smaller, more cholesteryl ester-rich VLDL (Sf 20-60), it is likely that pre-beta-VLDL are precursors of beta-VLDL. Although beta-VLDL were not found in type V hyperlipidemic E3/3 subjects, they were induced by intravenous heparinization, suggesting that lipolysis of pre-beta-VLDL in vivo can result in beta-VLDL formation. Similarly, heparinization of a dys-beta subject produced more beta-VLDL, at the expense of pre-beta-VLDL. The pre-beta-VLDL from normolipidemic and type V hyperlipidemic E3/3 subjects, respectively, had 90 and 280 times the affinity for the apo-B,E(LDL) receptor than did the pre-beta-VLDL from dys-beta subjects. Heparin-induced beta-VLDL from type V hyperlipidemic subjects had a sixfold higher binding affinity than did heparin-induced beta-VLDL from dys-beta subjects. These data suggest that pre-beta-VLDL from E2/2 subjects interact poorly with lipoprotein receptors in vivo, decreasing their receptor-mediated clearance and increasing their conversion to beta-VLDL during lipolytic processing.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2841358      PMCID: PMC303558          DOI: 10.1172/JCI113642

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  65 in total

1.  Phosphorus assay in column chromatography.

Authors:  G R BARTLETT
Journal:  J Biol Chem       Date:  1959-03       Impact factor: 5.157

2.  The alpha2 lipoproteins of human serum; correlation of ultracentrifugal and electrophoretic properties.

Authors:  H G KUNKEL; R TRAUTMAN
Journal:  J Clin Invest       Date:  1956-06       Impact factor: 14.808

3.  Type III hyperlipoproteinemia: rise in high-density lipoprotein levels in response to therapy.

Authors:  J M Falko; J L Witztum; G Schonfeld; S W Weidman; J B Kolar
Journal:  Am J Med       Date:  1979-02       Impact factor: 4.965

4.  Suppression of 3-hydroxy-3-methylglutaryl-CoA reductase by low density lipoproteins produced in vitro by lipoprotein lipase action on nonsuppressive very low density lipoproteins.

Authors:  A L Catapano; S H Gianturco; P K Kinnunen; S Eisenberg; A M Gotto; L C Smith
Journal:  J Biol Chem       Date:  1979-02-25       Impact factor: 5.157

5.  Role of lysine residues of plasma lipoproteins in high affinity binding to cell surface receptors on human fibroblasts.

Authors:  K H Weisgraber; T L Innerarity; R W Mahley
Journal:  J Biol Chem       Date:  1978-12-25       Impact factor: 5.157

6.  Simultaneous analysis of families of sigmoidal curves: application to bioassay, radioligand assay, and physiological dose-response curves.

Authors:  A DeLean; P J Munson; D Rodbard
Journal:  Am J Physiol       Date:  1978-08

7.  Effect of apoproteins on hepatic uptake of triglyceride emulsions in the rat.

Authors:  F Shelburne; J Hanks; W Meyers; S Quarfordt
Journal:  J Clin Invest       Date:  1980-03       Impact factor: 14.808

8.  Receptor binding of cholesterol-induced high-density lipoproteins containing predominantly apoprotein E to cultured fibroblasts with mutations at the low-density lipoprotein receptor locus.

Authors:  T L Innerarity; R E Pitas; R W Mahley
Journal:  Biochemistry       Date:  1980-09-02       Impact factor: 3.162

9.  Lipolysis produces changes in the immunoreactivity and cell reactivity of very low density lipoproteins.

Authors:  G Schonfeld; W Patsch; B Pfleger; J L Witztum; S W Weidman
Journal:  J Clin Invest       Date:  1979-11       Impact factor: 14.808

10.  Determinants of hepatic uptake of triglyceride-rich lipoproteins and their remnants in the rat.

Authors:  E Windler; Y Chao; R J Havel
Journal:  J Biol Chem       Date:  1980-06-10       Impact factor: 5.157

View more
  4 in total

1.  Accumulation of apolipoprotein E-rich high density lipoproteins in hyperalphalipoproteinemic human subjects with plasma cholesteryl ester transfer protein deficiency.

Authors:  S Yamashita; D L Sprecher; N Sakai; Y Matsuzawa; S Tarui; D Y Hui
Journal:  J Clin Invest       Date:  1990-09       Impact factor: 14.808

2.  High receptor binding affinity of lipoproteins in atypical dysbetalipoproteinemia (type III hyperlipoproteinemia).

Authors:  D A Chappell
Journal:  J Clin Invest       Date:  1989-12       Impact factor: 14.808

3.  Type III hyperlipoproteinemia and spontaneous atherosclerosis in mice resulting from gene replacement of mouse Apoe with human Apoe*2.

Authors:  P M Sullivan; H Mezdour; S H Quarfordt; N Maeda
Journal:  J Clin Invest       Date:  1998-07-01       Impact factor: 14.808

Review 4.  Hyperlipoproteinemia type 3: the forgotten phenotype.

Authors:  Paul N Hopkins; Eliot A Brinton; M Nazeem Nanjee
Journal:  Curr Atheroscler Rep       Date:  2014-09       Impact factor: 5.113

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.